12/16
07:05 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
12/6
01:00 pm
dnli
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]
12/6
10:57 am
dnli
Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
Low
Report
Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
12/5
08:10 am
dnli
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]
12/5
08:00 am
dnli
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
Low
Report
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
11/16
08:59 am
dnli
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
Medium
Report
Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]
11/15
08:48 am
dnli
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
High
Report
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely [Yahoo! Finance]
11/8
11:57 am
dnli
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
Medium
Report
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging [Yahoo! Finance]
11/7
08:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
11/7
02:45 am
dnli
Denali Therapeutics GAAP EPS of -$0.63 [Seeking Alpha]
Low
Report
Denali Therapeutics GAAP EPS of -$0.63 [Seeking Alpha]
11/6
04:01 pm
dnli
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
Low
Report
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
11/1
01:38 pm
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Jefferies Financial Group Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target raised by analysts at Jefferies Financial Group Inc. from $40.00 to $45.00. They now have a "buy" rating on the stock.
10/11
10:35 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
10/10
09:36 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/7
08:10 am
dnli
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.
Medium
Report
Denali Therapeutics Inc. (NASDAQ: DNLI) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating.